대한정형외과학회지 (Journal of the Korean Orthopaedic Association)

  • 제55권5호
  • /
  • Pages.397-404
  • /
  • 2020
  • /
  • 1226-2102(pISSN)
  • /
  • 2005-8918(eISSN)
대한정형외과학회 (Korean Orthopaedic Association)
권호 표지
DOI QR코드

DOI QR Code

연부조직에 발생한 평활 근육종의 임상양상 및 치료 결과

Leiomyosarcoma of the Somatic Soft Tissue: Clinical Manifestation and Treatment Results

  • Kim, Yong Sung (Department of Orthopedic Surgery, Korea Cancer Center Hospital) ;
  • Kong, Chang-Bae (Department of Orthopedic Surgery, Korea Cancer Center Hospital) ;
  • Cho, Wan-Hyeong (Department of Orthopedic Surgery, Korea Cancer Center Hospital) ;
  • Jeon, Dae-Geun (Department of Orthopedic Surgery, Korea Cancer Center Hospital) ;
  • Kim, Kyung Hoon (Department of Orthopedic Surgery, Korea Cancer Center Hospital) ;
  • Song, Won Seok (Department of Orthopedic Surgery, Korea Cancer Center Hospital)
  • 투고 : 2019.08.01
  • 심사 : 2019.11.21
  • 발행 : 2020.10.30
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 본 연구의 목적은 연부조직에 발생한 평활 근육종 환자의 치료 결과를 후향적으로 분석하여 생존율과 재발 및 전이의 양상 등 치료 결과를 알아보고 예후에 영향을 미치는 인자를 분석하고자 한다. 대상 및 방법: 2001년 1월부터 2017년 12월까지 본원에서 연부조직에 발생한(사지 및 체간) 평활 근육종으로 치료 받은 72명의 환자를 대상으로 하였다. 치료 후 재발, 전이 발생, 생존율 및 생존의 예후 인자를 조사하였다. 생존자 중 1년 이상 추시되지 않은 증례는 제외하였다. 평균 추시 기간은 41개월(범위, 7-163개월)이었다. 결과: 전체 환자의 5년 생존율은 73.6%, 10년 생존율은 66.2%였다. 생존율에 영향을 미치는 인자는 종양의 크기(p=0.018), 병리학적 등급(p=0.017), 국소재발(p=0.04)이었다. 전이성 병변은 72명의 환자 중 23명(31.9%)의 환자에서 발생하였으며 전이 후 사망까지의 중간값은 15.6개월(범위, 3-78개월)이었다. 결론: 연부조직에 발생하는 평활 근육종은 주로 하지에 발생하며 종양의 크기, 병리학적 등급, 국소재발이 생존율에 영향을 미치고, 전이 후 생존율은 치료에도 불구하고 불량하였다.

Purpose: The purpose of this study was to evaluate the treatment outcome of leiomyosarcoma (LMS) of the somatic soft tissue and investigate the prognostic factors. Materials and Methods: Seventy-two patients with soft tissue LMS (extremities and trunk) between 2001 and 2017 were reviewed retrospectively. The local recurrence and metastasis after treatment were examined. The survival rates and prognostic factors affecting survival were investigated. Only patients followed-up more than one year were included. The mean follow-up time was 41 months (range, 7-163 months). Results: The overall survival rates at five-year and 10-year were 73.6% and 66.2%, respectively. The tumor size (p=0.018), grade (p=0.017), and local recurrence (p=0.04) affected survival. Metastases developed in 31.9% (23/72) and the median post metastasis survival was 15.6 months (range, 3-78 months). Conclusion: LMS of the soft tissue developed mainly at the lower extremity. The tumor size, grade, and local recurrence were associated with survival. Post metastatic survival was generally poor despite treatment.

키워드

참고문헌

  1. Gladdy RA, Qin LX, Moraco N, Agaram NP, Brennan MF, Singer S. Predictors of survival and recurrence in primary leiomyosarcoma. Ann Surg Oncol. 2013;20:1851-7. https://doi.org/10.1245/s10434-013-2876-y
  2. George S, Serrano C, Hensley ML, Ray-Coquard I. Soft tissue and uterine leiomyosarcoma. J Clin Oncol. 2018;36:144-50.
  3. Gustafson P, Willen H, Baldetorp B, Ferno M, Akerman M, Rydholm A. Soft tissue leiomyosarcoma. A population-based epidemiologic and prognostic study of 48 patients, including cellular DNA content. Cancer. 1992;70:114-9. https://doi.org/10.1002/1097-0142(19920701)70:1<114::AID-CNCR2820700119>3.0.CO;2-U
  4. Massi D, Beltrami G, Mela MM, Pertici M, Capanna R, Franchi A. Prognostic factors in soft tissue leiomyosarcoma of the extremities: a retrospective analysis of 42 cases. Eur J Surg Oncol. 2004;30:565-72. https://doi.org/10.1016/j.ejso.2004.03.002
  5. Wang W, Hong J, Meng J, et al. Nomograms predict cancer-specific and overall survival of patients with primary limb leiomyosarcoma. J Orthop Res. 2019;37:1649-57. https://doi.org/10.1002/jor.24298
  6. Svarvar C, Bohling T, Berlin O, et al.; Scandinavian Sarcoma Group Leiomyosarcoma Working Group. Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group. Cancer. 2007;109:282-91. https://doi.org/10.1002/cncr.22395
  7. Abraham JA, Weaver MJ, Hornick JL, Zurakowski D, Ready JE. Outcomes and prognostic factors for a consecutive case series of 115 patients with somatic leiomyosarcoma. J Bone Joint Surg Am. 2012;94:736-44. https://doi.org/10.2106/JBJS.K.00460
  8. Daugaard S. Current soft-tissue sarcoma classifications. Eur J Cancer. 2004;40:543-8. https://doi.org/10.1016/j.ejca.2003.11.009
  9. Mankin HJ, Casas-Ganem J, Kim JI, Gebhardt MC, Hornicek FJ, Zeegen EN. Leiomyosarcoma of somatic soft tissues. Clin Orthop Relat Res. 2004;421:225-31. https://doi.org/10.1097/01.blo.0000119250.08614.82
  10. Farshid G, Pradhan M, Goldblum J, Weiss SW. Leiomyosarcoma of somatic soft tissues: a tumor of vascular origin with multivariate analysis of outcome in 42 cases. Am J Surg Pathol. 2002;26:14-24. https://doi.org/10.1097/00000478-200201000-00002
  11. Jensen ML, Jensen OM, Michalski W, Nielsen OS, Keller J. Intradermal and subcutaneous leiomyosarcoma: a clinicopathological and immunohistochemical study of 41 cases. J Cutan Pathol. 1996;23:458-63. https://doi.org/10.1111/j.1600-0560.1996.tb01435.x
  12. Hashimoto H, Daimaru Y, Tsuneyoshi M, Enjoji M. Leiomyosarcoma of the external soft tissues. A clinicopathologic, immunohistochemical, and electron microscopic study. Cancer. 1986;57:2077-88. https://doi.org/10.1002/1097-0142(19860515)57:10<2077::AID-CNCR2820571033>3.0.CO;2-T
  13. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14:1679-89. https://doi.org/10.1200/JCO.1996.14.5.1679
  14. Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001;91:1914-26. https://doi.org/10.1002/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3
  15. Koea JB, Leung D, Lewis JJ, Brennan MF. Histopathologic type: an independent prognostic factor in primary soft tissue sarcoma of the extremity? Ann Surg Oncol. 2003;10:432-40. https://doi.org/10.1245/ASO.2003.05.014
  16. Guillou L, Aurias A. Soft tissue sarcomas with complex genomic profiles. Virchows Arch. 2010;456:201-17. https://doi.org/10.1007/s00428-009-0853-4
  17. Agaram NP, Zhang L, LeLoarer F, et al. Targeted exome sequencing profiles genetic alterations in leiomyosarcoma. Genes Chromosomes Cancer. 2016;55:124-30. https://doi.org/10.1002/gcc.22318
  18. Larramendy ML, Kaur S, Svarvar C, Bohling T, Knuutila S. Gene copy number profiling of soft-tissue leiomyosarcomas by array-comparative genomic hybridization. Cancer Genet Cytogenet. 2006;169:94-101. https://doi.org/10.1016/j.cancergencyto.2006.01.008
  19. Grimer R, Judson I, Peake D, Seddon B. Guidelines for the management of soft tissue sarcomas. Sarcoma. 2010;2010:506182. https://doi.org/10.1155/2010/506182
  20. Nielsen TO, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet. 2002;359:1301-7. https://doi.org/10.1016/S0140-6736(02)08270-3